KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 85 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $627,433 | +7.0% | 65,154 | 0.0% | 0.00% | – |
| Q2 2023 | $586,386 | +16.8% | 65,154 | +2.0% | 0.00% | – |
| Q1 2023 | $501,995 | +17.7% | 63,867 | +1.2% | 0.00% | – |
| Q4 2022 | $426,664 | -53.4% | 63,116 | 0.0% | 0.00% | – |
| Q3 2022 | $916,000 | +48.0% | 63,116 | +0.3% | 0.00% | – |
| Q2 2022 | $619,000 | -28.2% | 62,899 | +7.7% | 0.00% | – |
| Q1 2022 | $862,000 | +13.4% | 58,415 | +1.7% | 0.00% | – |
| Q4 2021 | $760,000 | -16.5% | 57,415 | +10.2% | 0.00% | – |
| Q3 2021 | $910,000 | -21.1% | 52,098 | +8.2% | 0.00% | – |
| Q2 2021 | $1,154,000 | -4.2% | 48,161 | +2.7% | 0.00% | – |
| Q1 2021 | $1,205,000 | +88.9% | 46,897 | +39.6% | 0.00% | – |
| Q4 2020 | $638,000 | +63.2% | 33,587 | +8.4% | 0.00% | – |
| Q3 2020 | $391,000 | -0.5% | 30,990 | -4.4% | 0.00% | – |
| Q2 2020 | $393,000 | +71.6% | 32,421 | +8.7% | 0.00% | – |
| Q1 2020 | $229,000 | -57.0% | 29,829 | 0.0% | 0.00% | – |
| Q4 2019 | $532,000 | +67.8% | 29,829 | +9.3% | 0.00% | – |
| Q3 2019 | $317,000 | -47.6% | 27,293 | 0.0% | 0.00% | – |
| Q2 2019 | $605,000 | – | 27,293 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |